HC Wainwright Reaffirms “Neutral” Rating for Alumis (NASDAQ:ALMS)

Alumis (NASDAQ:ALMS)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $25.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 0.04% from the stock’s previous close.

ALMS has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. Guggenheim increased their target price on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Wells Fargo & Company raised their price target on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Finally, Chardan Capital lifted their price target on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Trading Up 2.4%

Shares of ALMS traded up $0.58 during mid-day trading on Friday, reaching $24.99. The company had a trading volume of 548,883 shares, compared to its average volume of 1,981,590. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -12.64 and a beta of -0.69. The firm has a fifty day simple moving average of $26.06 and a 200-day simple moving average of $25.27. Alumis has a fifty-two week low of $3.76 and a fifty-two week high of $31.35.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.05). The firm had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.47 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. As a group, equities analysts predict that Alumis will post -2.87 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alumis news, insider Mark Christopher Bradley sold 2,572 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the completion of the transaction, the insider owned 48,533 shares in the company, valued at $1,279,815.21. This represents a 5.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jorn Drappa sold 2,447 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $64,527.39. Following the completion of the sale, the insider directly owned 56,892 shares of the company’s stock, valued at $1,500,242.04. This trade represents a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 19,953 shares of company stock valued at $534,311. Company insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System increased its position in shares of Alumis by 2,222.5% during the first quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock worth $1,781,000 after acquiring an additional 77,364 shares during the last quarter. First Trust Advisors LP purchased a new position in Alumis in the first quarter valued at about $1,456,000. The Manufacturers Life Insurance Company grew its stake in Alumis by 775.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 154,634 shares of the company’s stock valued at $3,407,000 after purchasing an additional 136,973 shares in the last quarter. Swiss National Bank acquired a new stake in Alumis during the 1st quarter valued at approximately $2,815,000. Finally, Elmind Capital LP purchased a new stake in Alumis during the 1st quarter worth approximately $2,864,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.